miR-7-5p/FGFR4轴与胆囊癌患者预后的关系

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (812 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究miR-7-5p/FGFR4轴与胆囊癌(gall bladder cancer,GBC)患者预后的关系。方法选取武警特色医学中心2016-06至2018-06住院手术的GBC患者47例,收集胆囊癌组织(GBC组)及癌旁组织(PCLT组),选择同期良性胆囊疾病患者43例,收集良性胆囊组织(NC组),用RT-qPCR检测组织标本中成纤维生长因子受体4(fibroblast growth factor receptor 4,FGFR4)和miR-7-5p mRNA水平,并随访患者术后生存情况;分析miR-7-5p与FGFR4 mRNA表达水平的关系,根据miR-7-5p、FGFR4表达水平分为低表达亚组和高表达亚组,并分析其与胆囊癌患者预后的关系。结果与PCLT组和NC组比较,GBC组miR-7-5p mRNA表达水平明显下降,FGFR4 mRNA水平明显升高,差异有统计学意义(P<0.01);PCLT组和NC组比较,miR-7-5p mRNA表达水平下降,FGFR4 mRNA水平升高,但差异无统计学意义(P>0.05);miR-7-5p mRNA表达水平与FGFR4 mRNA表达水平负相关(r=-0.535,P=0.004);miR-7-5p mRNA表达水平与胆囊癌的分期、分化程度和淋巴转移情况相关(P=0.035,P=0.036,P=0.006),miR-7-5p mRNA低表达亚组患者生存率低于高表达亚组(P=0.047),FGFR4 mRNA低表达亚组生存率高于高表达亚组(P=0.033)。结论 miR-7-5p/FGFR4轴可能是影响GBC预后的指标之一。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王萌
	胡金朋
	王振国
	滕川

关键词 ：胆囊癌, miR-7-5p, 成纤维生长因子受体4, 预后

Abstract：Objective To explore the relationship between the miR-7-5p/FGFR4 axis and the prognosis of patients with gallbladder cancer (GBC).Methods A total of 47 GBC patients who underwent surgery in the Characteristic Medical Center of PAP between June 2016 and June 2018 were enrolled, whose gallbladder cancer tissues (GBC group) and paracancerous tissues (PCLT group) were collected. Another 43 patients with benign gallbladder disease were selected, and their benign gallbladder tissues were collected as the control group (NC group). The mRNA levels of fibroblast growth factor receptor 4 (FGFR4) and miR-7-5p were detected by RT-qPCR. The postoperative survival was followed up. The relationship between miR-7-5p and FGFR4 mRNA expressions was analyzed. According to the expression levels of miR-7-5p or FGFR4, these patients were divided into the low expression subgroup and high expression subgroup, and the relationship between the these expression levels and the prognosis of patients with gallbladder cancer was analyzed respectively.Results Compared with the PCLT or NC group, the level of miR-7-5p mRNA in the GBC group decreased, but the level of FGFR4 mRNA increased, and the difference was statistically significant (P<0.01). When compared with the NC group, the expression level of miR-7-5p mRNA in the PCLT group decreased, while the level of FGFR4 mRNA increased, but the difference was not statistically significant (P>0.05). The expression level of miR-7-5p mRNA was negatively correlated with that of FGFR4 mRNA (r=-0.535, P=0.004). The expression level of miR-7-5p mRNA was correlated with the stage, degree of differentiation and lymphatic metastasis of gallbladder carcinoma (P=0.035, P=0.036, P=0.006). The survival rate of patients in the miR-7-5p mRNA low expression subgroup was lower than that of the high expression subgroup (P=0.047), but that of patients in the FGFR4 mRNA low expression subgroup was higher than in the high expression subgroup (P=0.033).Conclusions The miR-7-5p/FGFR4 axis may be one of the indicators that affects the prognosis of GBC.

Key words： gallbladder cancer miR-7-5p fibroblast growth factor receptor 4 prognostic survival

收稿日期: 2021-10-08

ZTFLH:

R657.4

基金资助:天津市科技计划项目(16ZXHLSY00120,15ZXLCSY00040);武警部队后勤部科研项目(CWJ18L004)

通讯作者: 滕川, E-mail:tengchuan011@163.com

作者简介: 王萌,硕士研究生,主治医师。

引用本文:

王萌, 胡金朋, 王振国, 滕川. miR-7-5p/FGFR4轴与胆囊癌患者预后的关系[J]. 武警医学, 2022, 33(2): 93-97. WANG Meng, HU Jinpeng, WANG Zhenguo, TENG Chuan. Relationships between the miR-7-5p/FGFR4 axis and prognosis of patients with gallbladder cancer. Med. J. Chin. Peop. Armed Poli. Forc., 2022, 33(2): 93-97.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2022/V33/I2/93

[1]	Li Y L, Tian M, Zhang D Q ,et al. Long non-coding rna myosin light chain kinase antisense 1 plays an oncogenic role in gallbladder carcinoma by promoting chemoresistance and proliferation[J].Cancer Manag Res, 2021, 13(8): 6219-6230.
[2]	Graur F, Mois E, Margarit S, et al. Gallbladder carcinoma. Surgical management of gallblad-der carcinoma. An analysis of 37 cases[J]. Ann Ital Chir, 2018,89(6):501-506.
[3]	Roos E,Soer E C, Klompmaker S,et al. Crossing borders: a systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract[J].Crit Rev Oncol Hematol, 2019, 140(5): 8-16.
[4]	Pan Ch H, Nie W W, Wang J,et al. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors[J]. Eur J Med Chem, 2021, 225(7): 113794.
[5]	Tian S, Chen M, Wang B, et al. MiR-7-5p promotes hepatic stellate cell activation by targeting fibroblast growth factor receptor 4[J]. Gastroenterol Res Pract,2020,153(6):546-573.
[6]	Lagenfelt H, Blomstrand H, Elander N O. Real-world evidence on palliative gemcitabine and oxaliplatin (gemox) combination chemotherapy in advanced biliary tract cancer[J]. Cancers (Basel), 2021,13(14):3507.
[7]	Di Leva G, Garofalo M, Croce C M. Micro RNAs in cancer[J]. Annu Rev Pathol, 2014,56(9):287-314.
[8]	Giles K M, Brown R A, Epis M R, et al. miRNA-7-5p inhibits melanoma cell migration and invasion[J]. Biochem Biophys Res Commun,2013,430(2):706-710.
[9]	Xiao H. MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2[J]. Cell Mol Biol Lett, 2019,24(6):60.
[10]	Shi W, Song J, Gao Z, et al. Downregulation of miR-7-5p inhibits the tumorigenesis of esophagus cancer via targeting KLF4[J]. Onco Targets Ther, 2020,2020(13):9443-9453.
[11]	Yin C Y, Kong W, Jiang J, et al. MiR-7-5p inhibits cell migration and invasion in glioblastoma through targeting SATB1[J]. Oncol Lett, 2019,17(2):1819-1825.
[12]	Wu A L, Coulter S, Liddle C, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways[J]. PLoS One, 2011,6(3):e17868.
[13]	Lang L, Teng Y. Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies[J]. Cells, 2019,8(1):31.
[14]	Presta M, Chiodelli P, Giacomini A, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach[J]. Pharmacol Ther, 2017,179(11):171-187.
[15]	Mitchell R A, Luwor R B, Burgess A W. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics[J]. Exp Cell Res, 2018,371(1):1-19.
[16]	Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer[J]. Clin Cancer Res, 2015,21(12):2684-2694.
[17]	Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology[J]. Nat Rev Mol Cell Biol, 2013,14(3):166-180.
[18]	Hagel M, Miduturu C, Sheets M, et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway[J]. Cancer Discov, 2015, 23(5):424-437.
[19]	Choi M, Moschetta A, Bookout A L, et al. Identification of a hormonal basis for gallbladder filling[J]. Nat Med, 2006,12(3):1253-1255.
[20]	Repana D, Ross P.Targeting FGF19/FGFR4 pathway: a novel therapeutic strategy for hepatocellular carcinoma[J]. Diseases, 2015,3(4):294-305.
[21]	Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)[J]. Int J Mol Med, 2016,38(1):3-15.